Study on quality marker of Yiqi Fumai Lyophilized Injection
10.7501/j.issn.0253-2670.2019.02.004
- Author:
De-Kun LI
1
Author Information
1. Tianjin Tasly Pride Pharmaceutical Co., Ltd.
- Publication Type:Journal Article
- Keywords:
Drug property;
Fructose;
Ginsenoside Rb1;
Ginsenoside Rb2;
Ginsenoside Rc;
Ginsenoside Rf;
Ginsenoside Rg1;
Ginsenoside Rg3;
Ginsenoside Rh1;
Ginsenoside Ro;
Ophiopojaponin C;
Pennogenin-3-O-α-L-rhamnopyranosyl-(1→2)-β-D-xylopyranosyl- (1→4)-β-D-glucopyranoside;
Phiogenin-3-O-α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranoside;
Quality control;
Quality marker (Q-marker);
Schisandrin A;
Yiqi Fumai Lyophilized Injection
- From:
Chinese Traditional and Herbal Drugs
2019;50(2):290-298
- CountryChina
- Language:Chinese
-
Abstract:
Yiqi Fumai Lyophilized Injection is a modern preparation composed of Panax ginseng, Ophiopogon japonicas, and Schisandra chinensis. Clinically, it is mainly used for the treatment of cardiovascular diseases such as angina pectoris of coronary heart disease and chronic cardiac insufficiency. According to the concept of quality markers (Q-markers), the Q-markers of Yiqi Fumai Lyophilized Injection were predicted and analyzed from the aspects of chemical components, drug effect, network pharmacology, pharmacokinetics, and drug property. Based on the above studies, 13 components of ginsenosides Rb1, Rg1, Rf, Rh1, Rc, Rb2, Ro, Rg3, ophiopojaponin C, phiogenin-3-O-α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranoside, pennogenin-3-O-α-L-rhamnopyranosyl-(1→2)- β-D-xylopyranosyl-(1→4)-β-D-glucopyranoside, fructose, and schisandrin A were identified as Q-markers. According to the Q-markers, we established quality system for process control. The study of Yiqi Fumai Lyophilized Injection based on Q-markers can provide new research ideas for quality assessment of traditional Chinese materia medica injection.
